BioArctic Management
Management criteria checks 3/4
BioArctic's CEO is Gunilla Osswald, appointed in Jan 2014, has a tenure of 10.25 years. total yearly compensation is SEK22.38M, comprised of 19.8% salary and 80.2% bonuses, including company stock and options. directly owns 0.11% of the company’s shares, worth SEK18.81M. The average tenure of the management team and the board of directors is 5.3 years and 10.4 years respectively.
Key information
Gunilla Osswald
Chief executive officer
kr22.4m
Total compensation
| CEO salary percentage | 19.8% |
| CEO tenure | 10.3yrs |
| CEO ownership | 0.1% |
| Management average tenure | 5.3yrs |
| Board average tenure | 10.4yrs |
Recent management updates
Recent updates
Revenues Tell The Story For BioArctic AB (publ) (STO:BIOA B)
Apr 13
News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat
Feb 19News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat
Feb 03Investors Interested In BioArctic AB (publ)'s (STO:BIOA B) Revenues
Dec 23With EPS Growth And More, BioArctic (STO:BIOA B) Makes An Interesting Case
Nov 12BioArctic AB (publ) (STO:BIOA B) Analysts Are Way More Bearish Than They Used To Be
Jul 21Analysts Have Lowered Expectations For BioArctic AB (publ) (STO:BIOA B) After Its Latest Results
Jul 15New Forecasts: Here's What Analysts Think The Future Holds For BioArctic AB (publ) (STO:BIOA B)
Jul 07Things Look Grim For BioArctic AB (publ) (STO:BIOA B) After Today's Downgrade
May 06Companies Like BioArctic (STO:BIOA B) Can Afford To Invest In Growth
Mar 13Broker Revenue Forecasts For BioArctic AB (publ) (STO:BIOA B) Are Surging Higher
Nov 30We're Not Worried About BioArctic's (STO:BIOA B) Cash Burn
Sep 16We're Interested To See How BioArctic (STO:BIOA B) Uses Its Cash Hoard To Grow
Apr 04We Think BioArctic (STO:BIOA B) Can Easily Afford To Drive Business Growth
Dec 05BioArctic AB (publ) (STO:BIOA B) Shares Could Be 42% Below Their Intrinsic Value Estimate
Sep 15BioArctic (STO:BIOA B) Is In A Strong Position To Grow Its Business
Aug 23Is BioArctic AB (publ) (STO:BIOA B) Trading At A 41% Discount?
Jun 03Shareholders Will Probably Not Have Any Issues With BioArctic AB (publ)'s (STO:BIOA B) CEO Compensation
Apr 29Is BioArctic's (STO:BIOA B) Share Price Gain Of 291% Well Earned?
Mar 14CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | kr22m | kr4m | kr229m |
| Sep 30 2023 | n/a | n/a | kr259m |
| Jun 30 2023 | n/a | n/a | kr270m |
| Mar 31 2023 | n/a | n/a | kr327m |
| Dec 31 2022 | kr9m | kr5m | -kr11m |
| Sep 30 2022 | n/a | n/a | kr28m |
| Jun 30 2022 | n/a | n/a | -kr147m |
| Mar 31 2022 | n/a | n/a | -kr135m |
| Dec 31 2021 | kr5m | kr3m | -kr120m |
| Sep 30 2021 | n/a | n/a | -kr114m |
| Jun 30 2021 | n/a | n/a | -kr97m |
| Mar 31 2021 | n/a | n/a | -kr101m |
| Dec 31 2020 | kr5m | kr3m | -kr69m |
| Sep 30 2020 | n/a | n/a | -kr72m |
| Jun 30 2020 | n/a | n/a | -kr60m |
| Mar 31 2020 | n/a | n/a | kr78m |
| Dec 31 2019 | kr7m | kr3m | kr88m |
| Sep 30 2019 | n/a | n/a | kr441m |
| Jun 30 2019 | n/a | n/a | kr475m |
| Mar 31 2019 | n/a | n/a | kr380m |
| Dec 31 2018 | kr5m | kr3m | kr382m |
| Sep 30 2018 | n/a | n/a | kr58m |
| Jun 30 2018 | n/a | n/a | kr32m |
| Mar 31 2018 | n/a | n/a | kr29m |
| Dec 31 2017 | kr3m | kr2m | kr15m |
Compensation vs Market: Gunilla's total compensation ($USD2.05M) is above average for companies of similar size in the Swedish market ($USD790.54K).
Compensation vs Earnings: Gunilla's compensation has been consistent with company performance over the past year.
CEO
Gunilla Osswald (62 yo)
10.3yrs
Tenure
kr22,378,000
Compensation
Dr. Gunilla Osswald, PhD has been the Chief Executive Officer and President of BioArctic AB (publ) since 2014. Dr. Osswald has been a Director of Egetis Therapeutics AB (publ) (formerly known as PledPharma...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President & CEO | 10.3yrs | kr22.38m | 0.11% SEK 18.8m | |
| Co-Founder | 21.3yrs | kr390.00k | 0% SEK 0 | |
| Co-Founder | 21.3yrs | kr2.54m | 33.43% SEK 5.9b | |
| Chief Financial Officer | less than a year | no data | no data | |
| Chief Research Officer & Head of Research | no data | no data | 0.054% SEK 9.5m | |
| VP of Pre-Clinical Development & Chief Scientific Officer | 18.3yrs | no data | 0.063% SEK 11.1m | |
| VP and Head of IR & Communication | 3.9yrs | no data | 0.012% SEK 2.0m | |
| General Counsel and Head of Legal & IP | no data | no data | no data | |
| Head of Public Affairs | 2yrs | no data | no data | |
| Head of Marketing | 2.2yrs | no data | no data | |
| Vice President of Human Resources | 5.3yrs | no data | no data | |
| VP & Head of CMC | no data | no data | 0.011% SEK 1.9m |
5.3yrs
Average Tenure
62yo
Average Age
Experienced Management: BIOA B's management team is seasoned and experienced (5.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 21.3yrs | kr390.00k | 0% SEK 0 | |
| Co-Founder | 21.3yrs | kr2.54m | 33.43% SEK 5.9b | |
| Independent Chairman | 6.6yrs | kr621.00k | 0.091% SEK 15.9m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of the Scientific Board | no data | no data | no data | |
| Independent Director | 5.9yrs | kr316.00k | 0.031% SEK 5.4m | |
| Independent Vice Chairman | 14.3yrs | kr406.00k | 0.14% SEK 24.4m | |
| Independent Director | 2.9yrs | kr318.00k | 0.0036% SEK 629.2k | |
| Member of Scientific Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
10.4yrs
Average Tenure
74yo
Average Age
Experienced Board: BIOA B's board of directors are seasoned and experienced ( 10.4 years average tenure).